v3.25.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
ASSETS    
Cash and cash equivalents $ 99,118 $ 110,662
Restricted cash 1,461 1,738
Research and development incentives receivable 2,997 7,139
Prepaid expenses and other current assets 6,306 6,203
Total current assets 109,882 125,742
Property and equipment, net 6,201 7,373
Intangible assets, net 21,156 21,947
Right of use assets, net 3,855 4,384
Other assets 902 881
Total assets 141,996 160,327
Current liabilities:    
Accounts payable 1,357 2,474
Accrued expenses and other current liabilities 7,198 9,525
Deferred income 1,461 1,738
Operating lease liability - current 1,960 1,920
Total current liabilities 11,976 15,657
Non-current liabilities:    
Operating lease liability - non-current 9,959 10,087
Contingent consideration 2,652 2,650
Other non-current liabilities 1,400 1,360
Deferred tax liability, net 416 438
Total liabilities 26,403 30,192
Commitments and contingencies (Note 15)
Stockholders’ equity:    
Ordinary shares, £0.000025 nominal value; 40,339,395 shares authorized, issued and outstanding (December 31, 2024: authorized, issued and outstanding: 40,234,663) 1 1
Additional paid-in capital 393,944 393,474
Accumulated deficit (257,312) (237,664)
Accumulated other comprehensive loss – foreign currency translation adjustments (21,225) (25,868)
Total stockholders’ equity attributable to Barinthus Biotherapeutics plc shareholders 115,494 130,029
Noncontrolling interest 99 106
Total stockholders’ equity 115,593 130,135
Total liabilities and stockholders’ equity 141,996 160,327
Deferred A shares    
Stockholders’ equity:    
Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2024: authorized, issued and outstanding: 63,443) $ 86 $ 86